Welcome to DU!
The truly grassroots left-of-center political community where regular people, not algorithms, drive the discussions and set the standards.
Join the community:
Create a free account
Support DU (and get rid of ads!):
Become a Star Member
Latest Breaking News
General Discussion
The DU Lounge
All Forums
Issue Forums
Culture Forums
Alliance Forums
Region Forums
Support Forums
Help & Search
Funding Announced to Replace the Netherlands 62 Year Old Petten Reactor for Medical Isotopes
Funding announced for Pallas research reactorSubtitle:
Minister of Health, Welfare and Sport Ernst Kuipers has confirmed full funding has been allocated for the EUR1.68 billion (USD1.79 billion) estimated public investment required for the Pallas research reactor in Petten, the Netherlands.
An excerpt:
He said last September that the ministry was to spend EUR129 million per year, and has announced this week that an outstanding EUR320 million was now also covered in the budget. He also said that the process of getting approval under European Union state aid rules, was also under way.
Bertholt Leeftink, CEO of NRG-Pallas, said: "This decision is confirmation that the Pallas reactor is of strategic importance for the Netherlands and Europe. It will strengthen the security of medical isotopes supply for nuclear medicine. For patients, it means faster access to innovative (cancer) treatments."
He said it would help the Netherlands to expand its position in the world market for medical isotopes and nuclear technological research and "will preserve high-quality knowledge and employment in the North Holland headland".
Peter Dijk, Pallas programme director, called it "tremendous news ... with this decision we can proceed with the preparatory works and attract a contractor for realisation of the new build".
The Pallas research reactor is to be built at Petten to replace the existing High Flux Reactor (HFR). The 45 MW HFR started operating in September 1960, since when its use has largely been shifted from nuclear materials testing to fundamental research and the production of medical radioisotopes. The reactor - operated by NRG on behalf of the European Union's Joint Research Centre - has for a long time supplied about 60% of Europe's and 30% of the world's use of medical radioactive sources...
Bertholt Leeftink, CEO of NRG-Pallas, said: "This decision is confirmation that the Pallas reactor is of strategic importance for the Netherlands and Europe. It will strengthen the security of medical isotopes supply for nuclear medicine. For patients, it means faster access to innovative (cancer) treatments."
He said it would help the Netherlands to expand its position in the world market for medical isotopes and nuclear technological research and "will preserve high-quality knowledge and employment in the North Holland headland".
Peter Dijk, Pallas programme director, called it "tremendous news ... with this decision we can proceed with the preparatory works and attract a contractor for realisation of the new build".
The Pallas research reactor is to be built at Petten to replace the existing High Flux Reactor (HFR). The 45 MW HFR started operating in September 1960, since when its use has largely been shifted from nuclear materials testing to fundamental research and the production of medical radioisotopes. The reactor - operated by NRG on behalf of the European Union's Joint Research Centre - has for a long time supplied about 60% of Europe's and 30% of the world's use of medical radioactive sources...
